XML 20 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 47,247,000 $ 74,085,000
Investment in Eton Pharmaceuticals 8,681,000
Accounts receivable, net 116,373,000 36,261,000
Inventories 10,702,000 10,867,000
Prepaid expenses and other current assets 15,329,000 9,588,000
Total current assets 189,651,000 139,482,000
Property, plant and equipment, net 3,734,000 3,521,000
Capitalized software costs, net 1,751,000 2,138,000
Operating lease right-of-use assets, net 8,554,000 6,785,000
Intangible assets, net 184,949,000 159,906,000
Goodwill 332,000 332,000
TOTAL ASSETS 388,971,000 312,164,000
Current liabilities    
Accounts payable and accrued expenses 41,406,000 24,581,000
Accrued rebates and copay assistance 39,900,000 18,432,000
Accrued payroll and related liabilities 9,496,000 5,450,000
Deferred revenue and customer deposits 44,000 75,000
Current portion of operating lease obligations 497,000 806,000
Total current liabilities 91,343,000 49,344,000
Operating lease obligations, net of current portion 8,792,000 6,524,000
Notes payable, net of unamortized debt discounts 219,539,000 185,885,000
TOTAL LIABILITIES 319,674,000 241,753,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY    
Common stock, $0.001 par value, 50,000,000 shares authorized, 35,622,214 and 35,168,260 shares issued and outstanding at December 31, 2024 and 2023, respectively 35,000 35,000
Additional paid-in capital 221,002,000 204,635,000
Accumulated deficit (151,385,000) (133,904,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY 69,652,000 70,766,000
Noncontrolling interests (355,000) (355,000)
TOTAL STOCKHOLDERS’ EQUITY 69,297,000 70,411,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 388,971,000 $ 312,164,000